Market Research Logo

Renal Cluster Drug Development Pipeline Review, 2017

Renal Cluster Drug Development Pipeline Review, 2017

Summary


This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and also features dormant and discontinued projects.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. There are a total of 39 products in development for this indication, by 28 companies and five academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Pharmaxis, Cellmid and Vascular Biogenics.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. There are a total of 59 products in development for this indication, by 48 companies and two academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Apceth Biopharma, AstraZeneca, Bayer, Evotec, Novartis, Sarfez Pharmaceuticals and Vidasym.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. There are a total of 36 products in development for this indication, by 34 companies and one academic institution. A number of companies are operating in this space, with A1M Pharma alone developing multiple programs within the area.

Finally, kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Due to differences between the two patients, an autoimmune reaction against the donor kidney may occur in the recipient. There are a total of 39 products in development for this indication, by 33 companies and two academic institutions. Key companies operating in this pipeline space include Astellas Pharma, GlaxoSmithKline, Hillhurst Biopharmaceuticals and Kyowa Hakko Kirin.

While kidney transplant rejection treatments are largely focused on immune system molecular targets such as tumor necrosis factor alpha and complement factors, a range of cellular signaling components are being pursued in the other three key indications, including the activin receptors, cyclin dependent kinases, and growth factor receptors.

Scope

  • Which companies are the most active within the pipeline for renal cluster therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of renal cluster therapeutics?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Renal Cluster Report Coverage
    • Kidney Fibrosis – Overview
    • Chronic Kidney Disease (Chronic Renal Failure) –Overview
    • Acute Renal Failure (ARF) (Acute Kidney Injury) –Overview
    • Kidney Transplant Rejection – Overview
  • Therapeutics Development
    • Kidney Fibrosis
      • Table Figure 1: Number of Products under Development for Kidney Fibrosis
      • Table Number of Products under Development for Kidney Fibrosis
      • Table Figure 2: Number of Products under Development by Companies, Kidney Fibrosis
      • Table Number of Products under Development by Companies, Kidney Fibrosis
      • Table Number of Products under Development by Universities/Institutes, Kidney Fibrosis
      • Table Products under Development by Companies, Kidney Fibrosis
      • Table Products under Development by Universities/Institutes, Kidney Fibrosis
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 3: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)
      • Table Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 4: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 5: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
    • Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Figure 6: Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Figure 7: Number of Products under Development by Companies, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Number of Products under Development by Companies, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Number of Products under Development by Universities/Institutes, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Products under Development by Companies, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Products under Development by Universities/Institutes, Acute Renal Failure (ARF) (Acute Kidney Injury)
    • Kidney Transplant Rejection
      • Table Figure 8: Number of Products under Development for Kidney Transplant Rejection
      • Table Number of Products under Development for Kidney Transplant Rejection
      • Table Figure 9: Number of Products under Development by Companies, Kidney Transplant Rejection
      • Table Number of Products under Development by Companies, Kidney Transplant Rejection
      • Table Figure 10: Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection
      • Table Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection
      • Table Products under Development by Companies, Kidney Transplant Rejection
      • Table Products under Development by Universities/Institutes, Kidney Transplant Rejection
  • Therapeutics Assessment
    • Kidney Fibrosis
      • Table Figure 11: Number of Products by Top 10 Targets, Kidney Fibrosis
      • Table Figure 12: Number of Products by Stage and Top 10 Targets, Kidney Fibrosis
      • Table Number of Products by Stage and Target, Kidney Fibrosis
      • Table Figure 13: Number of Products by Top 10 Mechanism of Actions, Kidney Fibrosis
      • Table Figure 14: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Fibrosis
      • Table Number of Products by Stage and Mechanism of Action, Kidney Fibrosis
      • Table Figure 15: Number of Products by Routes of Administration, Kidney Fibrosis
      • Table Figure 16: Number of Products by Stage and Routes of Administration, Kidney Fibrosis
      • Table Number of Products by Stage and Route of Administration, Kidney Fibrosis
      • Table Figure 17: Number of Products by Molecule Types, Kidney Fibrosis
      • Table Figure 18: Number of Products by Stage and Molecule Types, Kidney Fibrosis
      • Table Number of Products by Stage and Molecule Type, Kidney Fibrosis
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 19: Number of Products by Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 20: Number of Products by Stage and Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Number of Products by Stage and Target, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 21: Number of Products by Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 22: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Number of Products by Stage and Mechanism of Action, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 23: Number of Products by Top 10 Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 24: Number of Products by Stage and Top 10 Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Number of Products by Stage and Route of Administration, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 25: Number of Products by Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Figure 26: Number of Products by Stage and Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure)
      • Table Number of Products by Stage and Molecule Type, Chronic Kidney Disease (Chronic Renal Failure)
    • Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Figure 27: Number of Products by Top 10 Targets, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Figure 28: Number of Products by Stage and Top 10 Targets, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Number of Products by Stage and Target, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Figure 29: Number of Products by Top 10 Mechanism of Actions, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Figure 30: Number of Products by Stage and Top 10 Mechanism of Actions, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Number of Products by Stage and Mechanism of Action, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Figure 31: Number of Products by Routes of Administration, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Figure 32: Number of Products by Stage and Routes of Administration, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Number of Products by Stage and Route of Administration, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Figure 33: Number of Products by Molecule Types, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Figure 34: Number of Products by Stage and Molecule Types, Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Number of Products by Stage and Molecule Type, Acute Renal Failure (ARF) (Acute Kidney Injury)
    • Kidney Transplant Rejection
      • Table Figure 35: Number of Products by Top 10 Targets, Kidney Transplant Rejection
      • Table Figure 36: Number of Products by Stage and Top 10 Targets, Kidney Transplant Rejection
      • Table Number of Products by Stage and Target, Kidney Transplant Rejection
      • Table Figure 37: Number of Products by Top 10 Mechanism of Actions, Kidney Transplant Rejection
      • Table Figure 38: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Transplant Rejection
      • Table Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection
      • Table Figure 39: Number of Products by Routes of Administration, Kidney Transplant Rejection
      • Table Figure 40: Number of Products by Stage and Routes of Administration, Kidney Transplant Rejection
      • Table Number of Products by Stage and Route of Administration, Kidney Transplant Rejection
      • Table Figure 41: Number of Products by Top 10 Molecule Types, Kidney Transplant Rejection
      • Table Figure 42: Number of Products by Stage and Top 10 Molecule Types, Kidney Transplant Rejection
      • Table Number of Products by Stage and Molecule Type, Kidney Transplant Rejection
  • Companies Involved in Therapeutics Development
    • Kidney Fibrosis
      • Table Kidney Fibrosis – Pipeline by AbbVie Inc
      • Table Kidney Fibrosis – Pipeline by Allergan Plc
      • Table Kidney Fibrosis – Pipeline by Angion Biomedica Corp
      • Table Kidney Fibrosis – Pipeline by Apollo Endosurgery Inc
      • Table Kidney Fibrosis – Pipeline by BiOrion Technologies BV
      • Table Kidney Fibrosis – Pipeline by Cellmid Ltd
      • Table Kidney Fibrosis – Pipeline by Epigen Biosciences Inc
      • Table Kidney Fibrosis – Pipeline by Evotec AG
      • Table Kidney Fibrosis – Pipeline by Galectin Therapeutics Inc
      • Table Kidney Fibrosis – Pipeline by GenKyoTex SA
      • Table Kidney Fibrosis – Pipeline by Horizon Pharma Plc
      • Table Kidney Fibrosis – Pipeline by Intercept Pharmaceuticals Inc
      • Table Kidney Fibrosis – Pipeline by Isarna Therapeutics GmbH
      • Table Kidney Fibrosis – Pipeline by MorphoSys AG
      • Table Kidney Fibrosis – Pipeline by Pharmaxis Ltd
      • Table Kidney Fibrosis – Pipeline by ProMetic Life Sciences Inc
      • Table Kidney Fibrosis – Pipeline by Regulus Therapeutics Inc
      • Table Kidney Fibrosis – Pipeline by Sirnaomics Inc
      • Table Kidney Fibrosis – Pipeline by Symic Biomedical Inc
      • Table Kidney Fibrosis – Pipeline by Vascular Biogenics Ltd
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Angion Biomedica Corp
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by apceth Biopharma GmbH
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Astellas Pharma Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by AstraZeneca Plc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Bayer AG
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by BLR Bio LLC
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Boehringer Ingelheim GmbH
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Boryung Pharmaceutical Co Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Cellmid Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Chugai Pharmaceutical Co Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Complexa Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Corvidia Corp
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by CTI BioPharma Corp
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Evotec AG
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by F. Hoffmann-La Roche Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Gilead Sciences Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by GNI Group Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Lupin Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Navya Biologicals Pvt Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Nippon Zoki Pharmaceutical Co Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Novartis AG
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Otsuka Holdings Co Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Prismic Pharmaceuticals Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Prolong Pharmaceuticals LLC
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by ProMetic Life Sciences Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Reata Pharmaceuticals Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Regulus Therapeutics Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Relypsa Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Resverlogix Corp
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Spotlight Innovation Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Taisho Pharmaceutical Co Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Toray Industries Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Tricida Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Unity Biotechnology Inc
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Vascular BioSciences
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by VESSL Therapeutics Ltd
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Pipeline by Vicore Pharma AB
    • Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by A1M Pharma AB
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Alloksys Life Sciences BV
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Am-Pharma BV
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Angion Biomedica Corp
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Atox Bio Ltd
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Cellmid Ltd
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Complexa Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by DiaMedica Therapeutics Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by DURECT Corp
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Evotec AG
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Exponential Biotherapies Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by F. Hoffmann-La Roche Ltd
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by G1 Therapeutics Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Kringle Pharma Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Mitotech SA
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by NephroGenex Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by NeuroVive Pharmaceutical AB
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Nyken BV
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by ProMetic Life Sciences Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Quark Pharmaceuticals Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Rediscovery Life Sciences
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Regulus Therapeutics Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by SBI Pharmaceuticals Co Ltd
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Spherium Biomed SL
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by STATegics Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Stealth BioTherapeutics Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Thrasos Therapeutics Inc
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Torrent Pharmaceuticals Ltd
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Pipeline by Xigen SA
    • Kidney Transplant Rejection
      • Table Kidney Transplant Rejection – Pipeline by Amgen Inc
      • Table Kidney Transplant Rejection – Pipeline by Angion Biomedica Corp
      • Table Kidney Transplant Rejection – Pipeline by Apellis Pharmaceuticals Inc
      • Table Kidney Transplant Rejection – Pipeline by Astellas Pharma Inc
      • Table Kidney Transplant Rejection – Pipeline by Biogen Inc
      • Table Kidney Transplant Rejection – Pipeline by Catalyst Biosciences Inc
      • Table Kidney Transplant Rejection – Pipeline by Corline Biomedical AB
      • Table Kidney Transplant Rejection – Pipeline by CSL Ltd
      • Table Kidney Transplant Rejection – Pipeline by GlaxoSmithKline Plc
      • Table Kidney Transplant Rejection – Pipeline by Grifols SA
      • Table Kidney Transplant Rejection – Pipeline by Hansa Medical AB
      • Table Kidney Transplant Rejection – Pipeline by Kyowa Hakko Kirin Co Ltd
      • Table Kidney Transplant Rejection – Pipeline by Magnus Life Ltd
      • Table Kidney Transplant Rejection – Pipeline by Noorik Biopharmaceuticals AG
      • Table Kidney Transplant Rejection – Pipeline by Novartis AG
      • Table Kidney Transplant Rejection – Pipeline by Opsona Therapeutics Ltd
      • Table Kidney Transplant Rejection – Pipeline by OSE Immunotherapeutics
      • Table Kidney Transplant Rejection – Pipeline by Pharmicell Co Ltd
      • Table Kidney Transplant Rejection – Pipeline by Pharming Group NV
      • Table Kidney Transplant Rejection – Pipeline by Prolong Pharmaceuticals LLC
      • Table Kidney Transplant Rejection – Pipeline by Quark Pharmaceuticals Inc
      • Table Kidney Transplant Rejection – Pipeline by Shire Plc
      • Table Kidney Transplant Rejection – Pipeline by Tiziana Life Sciences Plc
  • Dormant Projects
    • Kidney Fibrosis
      • Table Kidney Fibrosis – Dormant Projects
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Dormant Projects
    • Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Dormant Projects
    • Kidney Transplant Rejection
      • Table Kidney Transplant Rejection – Dormant Projects
  • Discontinued Products
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Table Chronic Kidney Disease (Chronic Renal Failure) –Discontinued Products
    • Acute Renal Failure (ARF) (Acute Kidney Injury)
      • Table Acute Renal Failure (ARF) (Acute Kidney Injury) –Discontinued Products
    • Kidney Transplant Rejection
      • Table Kidney Transplant Rejection – Discontinued Products
  • Product Development Milestones
    • Kidney Fibrosis
    • Chronic Kidney Disease (Chronic Renal Failure)
    • Acute Renal Failure (ARF) (Acute Kidney Injury)
    • Kidney Transplant Rejection
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook